December 21, 2021Open Access

Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of 89Zr-Labeled Anti-PD-L1 Antibody Formats

Key Points

Key points are not available for this paper at this time.

Abstract

This study highlights the potential of designing radioligands with shorter pharmacokinetics for PD-L1 immuno-PET imaging in a preclinical model and encourages further clinical translation of such radioligands.

Bookmark

View Full Paper

Cite This Study

Bouleau et al. (Tue,) studied this question.

synapsesocial.com/papers/6a033e4a200d7a04bd755d90 https://doi.org/https://doi.org/10.2967/jnumed.121.262967

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors2017 · 275 citations
2Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial2015 · 6,538 citations
3RODES software for dose assessment of rats and mice contaminated with radionuclides2017 · 15 citations
4Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn1999 · 218 citations
5An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers2020 · 14 citations

Bookmark

View Full Paper